OCTOBER 7, 2021 – The World Health Organization yesterday announced its recommendation for RTS,S – the only approved malaria vaccine (also known as Mosquirix) – for mass distribution in Africa, marking a significant milestone in the fight against one of the leading causes of death for children under five in the region.
Despite being preventable and treatable, malaria kills approximately 260,000 African children under the age of five every year. Developed by one of HPIC’s founding members, GlaxoSmithKline (GSK), the RTS,S vaccine was developed in Africa by African scientists following nearly a decade of clinical trials in seven countries.
HPIC welcomes this significant development in the fight against malaria and is proud to continue to support innovation in Africa through its ongoing partnership with GSK.
To learn more about HPIC’s work in the prevention and treatment of malaria and other preventable diseases in Africa, read about our HOPE project here.
Related to Health Partners International of Canada welcomes the development of the first approved malaria vaccine
Health Partners International Canada and Canadian Medical Assistance Teams partner to provide medical relief to Haiti
OAKVILLE, ON, August 20, 2021 – A shipment of Humanitarian Medical Kits bound for Haiti has left the Health Partners…
HPIC Sends First Canadian Shipment of Medicines to Beirut
August 26, 2020 | Toronto, Ontario – Thanks to the generosity of Canadian pharmaceutical companies, financial donors and volunteers, Health Partners…
How Did HPIC Improve The Pharmaceutical Supply Chain?
This online version of our infographic in the online issuu format shows how HPIC improved Afghanistan’s pharmaceutical supply chain through its Capacity…